ADArturo Domínguez

Arturo Domínguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arturo Domínguez has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fracture risk assessment in patients with ileal urinary diversion after radical cystectomy: a comprehensive evaluation integrating bone mineral density, trabecular bone score, and FRAX®

    by Arturo Domínguez, Enrique Casado, Jesús Muñoz-Rodríguez, Joan Prats, María Laura Grubicy, Núria Masip, Cristina Piqué, Clara Centeno, Teresa Bonfill, Diana Fuertes, et al.

    Summary: We conducted a comprehensive fracture risk assessment in 112 men with urinary diversion (UD) after radical cystectomy, integrating bone mineral density (BMD), trabecular bone score (TBS), and FRAX®. A substantial proportion met the diagnostic criteria for osteoporosis or had lower TBS values. These findings support routine skeletal assessment during follow-up. Purpose: Patients undergoing radical cystectomy with UD face an increased risk of fracture; however, this aspect remains poorly investigated. We aimed to provide an integrated evaluation of skeletal health and fracture risk in men with UD. Methods: We conducted a cross-sectional study of 112 men (mean age 70.6 ± 7.98 years; range 50–83) with ileal UD. BMD was measured using DXA, TBS was obtained from lumbar spine DXA images, and 10-year fracture risk was estimated using FRAX®. Logistic regression was used to identify predictors of osteoporosis and lower TBS values. Results: Osteoporosis was identified in 32.1% of patients, and 40.2% were classified in the lowest TBS category (TBS < 1.23). Only 12.5% had normal results for both BMD and TBS. Median FRAX-MOF was 3.9% (IQR 2.7–6.05) without BMD, 5.3% (2.98–7.82) with BMD, and 5.8% (3.4–9.5) when adjusted for TBS. Median FRAX-HIP was 1.35% (0.7–2.78), 1.8% (0.9–4.55) with BMD, and 2% (1–5.2) with TBS adjustment. Age (per year, OR = 1.11, 95% CI 1.02–1.20; p = 0.012) and BMI (per kg/m 2 , OR = 0.73, 95% CI 0.62–0.86; p < 0.001) were independently associated with osteoporosis, while serum creatinine (per mg/dL, OR = 2.11, 95% CI 1.08–4.11; p = 0.028), BMI (per kg/m 2 , OR = 0.91, 95% CI 0.83–0.99; p = 0.041), and prior fracture (OR = 5.23, 95% CI 2.08–13.13; p < 0.001) were associated with TBS < 1.23. Metabolic acidosis was not associated with adverse skeletal outcomes or higher FRAX estimates. Conclusions: Men with ileal UD showed reduced bone mass and a notable proportion of low TBS values, consistent with increased skeletal fragility and fracture risk. Structured bone health assessment should be considered during routine follow-up.

  • Open Access

    CT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning

    by Nicolás Feltes Benítez, Manuel Galdeano-Rubio, Jesus Muñoz-Rodriguez, Arturo Domínguez, Josep Maria Solé i Monné, Meritxell Pérez Márquez, Sergio Caballero del Pozo, Inma Díaz-Álvarez, Felipe Couñago, Saturio Paredes-Rubio

    Introduction: ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone-releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 nmol/L) and were moderately correlated (Spearman ρ = 0.43, p = 0.002; Pearson r = 0.51, p < 0.001). No baseline clinical, histologic, or biochemical variables reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p = 0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with more than half of cases achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories.


  • Open Access

    CT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning

    by Nicolas Feltes Benitez, Manuel Galdeano-Rubio, Josep Maria Sole i Monne, Jesús Muñoz-Rodriguez, Arturo Dominguez García, Meritxell Pérez Márquez, Sergio Caballero del Pozo, Inma Diaz Alvarez, Felipe Couñago, Saturio Paredes Rubio

    Introduction : ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone–releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 ng/mL) and were moderately correlated (Spearman ρ=0.43, p=0.002; Pearson r=0.51, p< 0.001). No baseline clinical, histologic, or biochemical variable reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p=0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with most patients achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs antagonist trajectories.

  • Why do patients with urinary diversions have an increased risk of bone fracture? A systematic review on risk factors for osteoporosis and bone mineral density loss in this group of patients

    by A. Domínguez García, J. Muñoz Rodríguez, J. Prats López, E. Casado Burgos, S. Cuadrench Solorzano, M.E. Zegrí de Olivar, A. Gavaldà Guillén, X. Serra Aracil


  • Pancreatitis, una presentación inusual de aumento escrotal

    by Víctor Parejo, Arturo Domínguez, Neus García, Àngel Prera, Joan Prats

  • Giant Prostatic Hyperplasia: Case Report of 3987 mL

    by Arturo Domínguez, Josep Gual, Jesús Muñoz-Rodríguez, Carlos Abad, Darío García-Rojo, Naim Hannaoui, Joan Prats